Global Chronic Obstructive Pulmonary Disease Market Forecasts to 2024 - What Role will Biologics Play in COPD? - Research and Markets

DUBLIN, August 10, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Chronic Obstructive Pulmonary Disease" report to their offering.

While the chronic obstructive pulmonary disease (COPD) market will see downward pressure from the arrival of generic versions of key marketed brands, new products will drive positive growth during 2015-24.

This report addresses the following questions:

- How will the emergence of numerous long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations and triple combinations impact the gold standard Spiriva?

- Which are the preferred LABA/LAMA combinations among pulmonologists?

- How will triple combination therapies fit into the COPD treatment algorithm?

- What role will administration frequency play in choice of therapy?

- How will the availability of generics affect sales of key marketed drugs?

- What role will biologics play in COPD?

Key Topics Covered:

FORECAST: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Advair (fluticasone/salmeterol)

- Anoro Ellipta (umeclidinium/vilanterol)

- Arcapta (indacaterol)

- Breo (fluticasone furoate/vilanterol)

- CHF 5 (beclometasone/formoterol/glycopyrrolate)

- Daliresp (roflumilast)

- Duaklir Genuair (aclidinium/formoterol)

- Dulera (mometasone/formoterol)

- FF/UMEC/VI (fluticasone/umeclidinium/vilanterol)

- Incruse (umeclidinium)

- Nucala (mepolizumab)

- PT  (formoterol/glycopyrrolate)

- PT (budesonide/glycopyrronium/Formoterol)

- Seebri Breezhaler (glycopyrrolate)

- Spiriva (tiotropium)

- Stiolto Respimat (olodaterol/tiotropium)

- Striverdi Respimat (olodaterol)

- Symbicort (budesonide/formoterol)

- Tudorza Pressair (aclidinium)

- Ultibro (indacaterol/glycopyrronium bromide)

- Primary Research Methodology

TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Disease Definition and Diagnosis

- Patient Segmentation

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends

- Unmet Needs in Chronic Obstructive Pulmonary Disease

- Pipeline Drugs and Future Treatment

EPIDEMIOLOGY: COPD IN THE US, JAPAN, AND 5EU 

- Disease Background

- Sources and Methodology

- Forecast

- Epidemiologist Insight

- Strengths and Limitations

- Bibliography

EPIDEMIOLOGY: COPD IN BRAZIL

- Disease Background

- Sources and Methodology

- Forecast

- Epidemiologist Insight

- Strengths and Limitations

- Bibliography

MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Product profile: Advair

- Product profile: Anoro

- Product profile: Arcapta Neohaler

- Product profile: Breo

- Product profile: Daliresp

- Product profile: Duaklir Genuair

- Product profile: Incruse

- Product profile: Seebri Breezhaler

- Product profile: Spiriva

- Product profile: Stiolto Respimat

- Product profile: Striverdi Respimat

- Product profile: Symbicort

- Product profile: Tudorza Pressair

- Product profile: Ultibro

PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Clinical Pipeline Overview

- Recently Discontinued Drugs

- Product profile (late stage): CHF 59

- Product profile (late stage): FF/UMEC/VI

- Product profile (late stage): Nucala

- Product profile (late stage): PT0

- Product profile (late stage): PT0

- Product profile (late stage): benralizumab

For more information visit http://www.researchandmarkets.com/research/7xmrck/chronic

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com